Answers are grounded in this paper and cite their sources.
Literature review reveals significant variation in willingness-to-pay estimates for health gains, indicating higher valuation for life extension over quality-of-life improvements.
There has been a rapid increase in the use of cost-effectiveness analysis, with quality adjusted life years (QALYs) as an outcome measure, in evaluating both medical technologies and public health interventions. Alongside, there is a growing literature on the monetary value of a QALY based on estimates of the willingness to pay (WTP). This paper conducts a review of the literature on the WTP for a QALY. In total, 24 studies containing 383 unique estimates of the WTP for a QALY are identified. Trimmed mean and median estimates amount to 74,159 and 24,226 Euros (2010 price level), respectively. In regression analyses, the results indicate that the WTP for a QALY is significantly higher if the QALY gain comes from life extension rather than quality of life improvements. The results also show that the WTP for a QALY is dependent on the size of the QALY gain valued.
No takes yet. Share an insight, caveat, or question.
Ryen et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: